Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAG-IDA in High Risk MDS or Secondary AML
NCT00487448Phase 4Completed
- Sponsor
- Fundación PETHEMA
- Start
- Jul 1998
- Primary completion
- May 2007
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of fludarabine, cytarabine, idarubicin, lenograstim in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Fundación PETHEMA. Started Jul 1998; status: completed.
02
Drugs
fludarabinecytarabineidarubicinlenograstim
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00487448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00487448.